Process for preparing dorzolamide
    5.
    发明授权
    Process for preparing dorzolamide 失效
    制备多佐胺的方法

    公开(公告)号:US08183391B2

    公开(公告)日:2012-05-22

    申请号:US12296834

    申请日:2007-04-16

    IPC分类号: C07D333/34 A61K31/38

    CPC分类号: C07D495/04

    摘要: A process for resolving dorzolamide trans racemate, which comprises reacting said racemate with (1S)-(+)-10-camphorsulfonic acid so obtaining the (4S,6S) enantiomer by selectively precipitating and recovering the camphorsulfonic acid salt thereof (dorzolamide camphorsulfonate), and neutralizing dorzolamide camphorsulfonate to obtain dorzolamide.

    摘要翻译: 一种解决多佐胺反式外消旋体的方法,其包括使所述外消旋体与(1S) - (+) - 10-樟脑磺酸反应,从而通过选择性沉淀并回收其樟脑磺酸盐(多佐胺樟脑磺酸盐),得到(4S,6S) 并中和多佐胺樟脑磺酸盐,得到多佐胺。

    PROCESS FOR PREPARING DORZOLAMIDE
    6.
    发明申请
    PROCESS FOR PREPARING DORZOLAMIDE 失效
    制备多氮杂多酰胺的方法

    公开(公告)号:US20090275759A1

    公开(公告)日:2009-11-05

    申请号:US12296834

    申请日:2007-04-16

    IPC分类号: C07D495/04

    CPC分类号: C07D495/04

    摘要: A process for resolving dorzolamide trans racemate, which comprises reacting said racemate with (1S)-(+)-10-camphorsulfonic acid so obtaining the (4S,6S) enantiomer by selectively precipitating and recovering the camphorsulfonic acid salt thereof (dorzolamide camphorsulfonate), and neutralizing dorzolamide camphorsulfonate to obtain dorzolamide.

    摘要翻译: 一种解决多佐胺反式外消旋体的方法,其包括使所述外消旋体与(1S) - (+) - 10-樟脑磺酸反应,从而通过选择性沉淀并回收其樟脑磺酸盐(多佐胺樟脑磺酸盐),得到(4S,6S) 并中和多佐胺樟脑磺酸盐,得到多佐胺。

    PROCESS FOR THE PREPARATION OF 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO (5,6)-CYCLOHEPTA-(1,2B) -PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER (LORATADINE)
    10.
    发明申请
    PROCESS FOR THE PREPARATION OF 4-(8-CHLORO-5,6-DIHYDRO-11H-BENZO (5,6)-CYCLOHEPTA-(1,2B) -PYRIDIN-11-YLIDENE)-1-PIPERIDINECARBOXYLIC ACID ETHYL ESTER (LORATADINE) 审中-公开
    制备4-(8-氯代-5,6-二氢-11H-苯并(5,6) - 环丙基 - (1,2B) - 吡啶-11-基] -1-哌啶羧酸乙酯的方法(LORATADINE )

    公开(公告)号:US20090005567A1

    公开(公告)日:2009-01-01

    申请号:US12207170

    申请日:2008-09-09

    摘要: A process and new oxazolinic intermediates for the preparation of 4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]-clohepta-[1,2-b]-pyridin-11-ylide-ne)-1-piperidinecarboxylic acid ethyl ester (loratadine) is described. The process starts from 2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-3-methyl-pyridine, a new intermediate to obtain loratadine. 2-(4,4-dimethyl-4,5-dihydro-oxazol-2-yl)-3-methyl-pyridine is condensed with 3-chloro-benzyl-chloride and the resultant product is treated with Grignard reagent of 4-chloro-N-methyl-piperidine. [3-(2-(3-chloro-phenyl)-ethyl]-pyridin-2-yl-]-1-(methyl-piperidin-4-yl)-methanone is obtained for subsequent hydrolysis. Starting from this last compound it is possible to obtain loratadine with known methods.

    摘要翻译: 用于制备4-(8-氯-5,6-二氢-11H-苯并[5,6] - 环庚烯 - [1,2-b] - 吡啶-11-内鎓盐的方法和新的恶唑啉中间体 )-1-哌啶羧酸乙酯(氯雷他定)。 该方法从2-(4,4-二甲基-4,5-二氢恶唑-2-基)-3-甲基 - 吡啶开始,得到氯雷他定的新中间体。 将2-(4,4-二甲基-4,5-二氢 - 恶唑-2-基)-3-甲基 - 吡啶与3-氯 - 苄基氯缩合,所得产物用格氏试剂4-氯 -N-甲基 - 哌啶。 得到[3-(2-(3-氯 - 苯基) - 乙基] - 吡啶-2-基] -1-(甲基 - 哌啶-4-基) - 甲酮用于随后的水解。 可以用已知的方法获得氯雷他定。